Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2019. https://doi.org/10.1007/s40259-019-00395-w.
European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 16 Mar 2020.
US Food and Drug Administration. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009: guidance for industry. https://www.fda.gov/media/119258/download. Accessed 16 Mar 2020.
WHO Expert Committee on Biological Standardization—Technical Report Series 977: Annex 2—guidelines on evaluation of similar biotherapeutic products (SBPs). https://apps.who.int/medicinedocs/documents/s19941en/s19941en.pdf. Accessed 16 Mar 2020.
Winegarden W. Incenting competition to reduce drug spending: the biosimilar opportunity. Pacific Research Institute. 2019. https://www.pacificresearch.org/wp-content/uploads/2019/07/BiosimilarsCompetition_F.pdf. Accessed 16 Mar 2020.
European Specialist Nurses Organisations: Switch management between similar biological medicines. 2018. http://www.esno.org/assets/biosimilar-nurses-guideline-final.pdf. Accessed 16 Mar 2020.
Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switch programme. J Crohns Colitis. 2017;11(6):690–6.
Frapaise FX. Biosimilars: patient perspectives, challenges and emerging solutions: current opinions. J Drug Res Dev. 2019. https://doi.org/10.16966/2470-1009.148.
Citizen Petition from Pfizer Inc. August 22, 2018. https://www.regulations.gov/document?D=FDA-2018-P-3281-0001. Accessed 19 Mar 2020.
Cohen HP, McCabe D. Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions. Stat News—First Opinion. June 18, 2019. https://www.statnews.com/2019/06/19/misinformation-biosimilars-market-preparation. Accessed 16 Mar 2020.
Building a wall against biosimilars. Nat Biotechnol. 2013. 31:264. https://doi.org/10.1038/nbt.2550.
Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33:2160–72.
Peyrin-Biroulet L, Lonnfors S, Avedano L, et al. Changes in inflammatory bowel disease patients perspectives on biosimilars: a follow-up survey. United Eur Gastroenterol J. 2019;7(10):1345–52.
Lamanna WC, Holzmann J, Cohen HP, et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opin Biol Ther. 2018;18(4):369–79.
Improving Access to Innovative Medicinal Therapies. Biologics price competition and innovation. https://www.fda.gov/media/78946/download. Accessed 16 Mar 2020.
US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product. Accessed 18 May 2020.
Liu Y, Yang M, Garg V, et al. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019;36:1851–77. https://doi.org/10.1007/s12325-019-00998-3. Accessed 17 Mar 2020.
Christl L, Lim S. Biosimilar and interchangeable products in the United States: scientific concepts, clinical use, and practical considerations. https://www.fda.gov/media/122832/download. Accessed 16 Mar 2020.
Cohen HP, Lamanna WC, Schiestl M. Totality of evidence and the role of clinical studies in establishing biosimilarity. In: Gutka HJ, Yang H, Kakar, editors. Biosimilars: regulatory, clinical and biopharmaceutical development, vol. 34., AAPS Advances in Pharmaceutical SciencesSwitzerland: Springer Nature; 2018. p. 601–28.
Krendyukov A, Schiestl M. Extrapolation concept at work with biosimilar: a decade of experience in oncology. EMSO Open. 2019;3:e000319. https://doi.org/10.1136/esmoopen-2017-000319. Accessed 16 Mar 2020.
U.S. Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry. http://www.fda.gov/media/124907/download. Accessed 16 Mar 2020.
Medicines for Europe. Oncology—the new era for biosimilar medicines. September 8, 2017. https://www.medicinesforeurope.com/news/oncology-the-new-era-for-biosimilar-medicines/. Accessed 17 Mar 2020.
European Medicines Agency and the European Commission. Biosimilars in the EU-Information guide for healthcare professionals (October 2019). https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 17 Mar 2020.
Center for Biosimilars. Panel grapples with the role of biosimilars in oncology. Center for Biosimilars. June 1, 2018. https://www.centerforbiosimilars.com/news/panel-grapples-with-the-role-of-biosimilars-in-oncology. Accessed 12 Feb 2020.
U.S. Food and Drug Administration. Part 15 Public hearing on facilitating competition and innovation in the biological products marketplace. September 4, 2018. Meeting transcript, p 198. https://www.fda.gov/media/124899/download. Accessed 3 June 2020.
Sattler C. Center for Biosimilars. European pharmacovigilance for biosimilars is robust and provides meaningful information. Center for Biosimilars (June 12, 2018). https://www.centerforbiosimilars.com/contributor/carlos-sattler/2018/06/letter-to-the-editor-european-pharmacovigilance-for-biosimilars-is-robust-and-provides-meaningful-information. Accessed 12 Feb 2020.
Vermeer NS, Giezen TJ, Zastavnik S, et al. Identifiability of biologicals in adverse drug reaction reports received from European clinical practice. Clin Pharmacol Ther. 2019;105(4):962–9.
Raffals LE, Nguyen GC, Rubin DT. Switching between biologics and biosimilars in inflammatory bowel disease. Clin Gastroentrol Heptol. 2019;17:818–23.
Kirkner RM. FDA’s Gottlieb aims to end biosimilars groundhog day. Managed Care, January 15, 2019. https://www.managedcaremag.com/archives/2019/1/fda-s-gottlieb-aims-end-biosimilars-groundhog-day. Accessed 18 May 2020.
Bruno E, Sadik K, Lafeuille MH, et al. Switching patterns among patients with chronic inflammatory diseases switching to an infliximab biosimilar or remaining on an originator infliximab. ACR/ARP Annual Meeting. 2019. Abstract 1115.
Alliance for Safe Biologic Medicines. Biosimilars 101. https://safebiologics.org/biosimilars-101/. Accessed 17 Mar 2020.
Weise M, Bielsky MC, De Smet K, Ehmann F, Giezen TJ, Gravanis I, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.
Murdoch B, Caulfield T. The law and ethics of switching from biologic to biosimilar in Canada. J Can Assoc Gastroenterol. 2020. https://doi.org/10.1093/jcag/gwz043.
McKinnon RA, Cook M, Liauw W, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32(1):27–52.
Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–78.
Milassin A, Fabian, Molnar T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Ther Adv Gastroenterol. 2019;12:1–11. https://doi.org/10.1177/1756284819842748.
Barbier L, Ebbers H, Declerck P, et al. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars—a systematic review. Clin Pharmacol Pharmacother. 2020. https://doi.org/10.1002/cpt.1836.
Kaplan GG, Ma C, Seow CH, et al. The argument against a biosimilar switch policy for infliximab in patients with inflammatory bowel disease living in Alberta. J Can Assoc Gastroenterol. 2020. https://doi.org/10.1093/jcag/gwz044.
Kay J. Overcoming barriers to biosimilars in inflammatory arthritis. Nat Rev Rheumatol. 2020;16:65–6.
Gasteiger C, Dalbeth N, Petrie K. The effects of message framing on patients’ perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthritis Care Res. 2019. https://doi.org/10.1002/acr.24012.
Tweehuysen L, Huiskes VJB, van den Bemt BJF, et al. Higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. Ann Rheum Dis. 2017. https://doi.org/10.1136/annrheumdis-2017-eular.2889.
Rezk MF, Pieper B. To see or NOsee: the debate on the nocebo effect and optimizing the use of biosimilars. Adv Ther. 2018;35:749–53. https://doi.org/10.1007/s12325-018-0768-z.
Kristensen LE, Alten R, Puig L, et al. Non-pharmacological effects in switching medication: the nocebo effect in switching from originator to biosimilar agent. BioDrugs. 2018;32:397–404. https://doi.org/10.1007/s40259-018-0306-1.
Pouillon L, Danese S, Hart A, et al. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. Aliment Pharmacol Ther. 2019;49:1181–7. https://doi.org/10.1111/apt.15223.
Glintborg B, Ibsen R, Bilbo REQ, Hetland ML, Kjelberg J. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open. 2019. https://doi.org/10.1136/rmdopen-2019-001016.
Gibofsy A, Skup M, Mittal M, Johnson SJ, Davis M, Chao J, et al. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017;33:1945–53.
Biosimilars Forum. Biosimilar FAQs. https://biosimilarsforum.org/biosimilars-insights/biosimilars-faqs/. Accessed 18 May 2020.
Industry Standard Research Report. ASBM European Prescribers Survey. 2019. https://safebiologics.org/wp-content/uploads/2020/06/EU-Survey-2019.pdf. Accessed 13 July 2020
Association for Affordable Medicines. Failure to launch-barriers to biosimilar market adoption. Sept 2019. https://www.biosimilarscouncil.org/wp-content/uploads/2019/09/AAM-Biosimilars-Council-Failure-to-Launch-2-web.pdf. Accessed 18 May 2020.
D’Amico F, Pouillon L, Argollo M, et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group. Dig Liver Dis. 2020;52(2):138–42. https://doi.org/10.1016/j.did.2019.11.004.
Joint Statement of the Food and Drug Administration and the Federal Trade Commission regarding a collaboration to advance competition in the biologics marketplace. Feb 3, 2020. https://www.fda.gov/media/134864/download. Accessed 17 Mar 2020.
US Food and Drug Administration. Promotional labeling and advertising considerations for prescription biological reference and biosimilar products: questions and answers-guidance for industry. https://www.fda.gov/media/134862/download. Accessed 17 Mar 2020.
ICMRA statement about confidence in biosimilar products (for healthcare professionals). July 2019. http://www.icmra.info/drupal/sites/default/files/2019-07/ICMRA_statement_about_confidence_in_biosimilar_product_HCP.PDF. Accessed 17 Mar 2020.
Heavner BB and Judson KR. A new guide for promotional labeling and advertising of biosimilar products. Center for Biosimilars (May 26, 2020) https://www.biosimilardevelopment.com/doc/a-new-guide-for-promotional-labeling-and-advertising-of-biosimilar-products-0001. Accessed 26 May 2020.
US Food and Drug Administration. Biosimilars are safe, effective treatment options. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Accessed 17 Mar 2020.
European Medicines Agency. Questions and answers for patients—biosimilars medicines explained. http://ec.europa.eu/DocsRoom/documents/26643. Accessed 17 Mar 2020.
Bridges SL Jr, White DW, Worthing AB, On behalf of the American College of Rheumatology, et al. The science behind biosimilars: entering a new era of biologic therapy. Arthritis Rheumatol. 2018;70(3):334–44.
Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology statement: biosimilars in Oncology. J Clin Oncol. 2018;36:1260–5. https://doi.org/10.1200/jco.2017.77.4893.
Academy of Managed Care Pharmacy. Biosimilars Resource Center. https://www.biosimilarsresourcecenter.org/. Accessed 17 Mar 2020.
Arthritis Foundation. Biosimilars: what you should know. https://arthritis.org/drug-guide/medication-topics/biosimilars-an-alternative-to-biologics. Accessed 17 Mar 2020.
American Cancer Society-Cancer Action Network. Understanding biologic and biosimilar drugs. https://www.fightcancer.org/policy-resources/understanding-biologic-and-biosimilar-drugs. Accessed 17 Mar 2020.
Biosimilars Forum. Biosimilars: a new era in medicine. https://biosimilarsforum.org/. Accessed 17 Mar 2020.
Biosimilars Council. Biosimilars 101. https://biosimilarscouncil.org/biosimilars-101/. Accessed 17 Mar 2020.
Crespi-Lofton J, Skelton JB. The growing role of biologics and biosimilars in the United States: perspectives from the APhA biologics and biosimilars stakeholder conference. J Am Pharm Assoc. 2017;57(5):e15–27. https://doi.org/10.1016/j.japh.2017.05.014.
International Alliance of Patient Organizations. Biologic medicines toolkit 2017. https://www.iapo.org.uk/biosimilars-toolkit. Accessed 15 May 2020.
US Food and Drug Administration. Biosimilar basics. 2019. https://www.fda.gov/media/130918/download. Accessed 15 May 2020.
US Food and Drug Administration. What is a biosimilar? 2019. https://www.fda.gov/media/108905/download. Accessed 15 May 2020.
Tan SS, Goonawardene N. Internet health information seeking and the patient-physician relationship: a systematic review. J Med Internet Res. 2017;19(1):e9. https://doi.org/10.2196/jmir.5729.
Pew Research Center. Health online 2013. https://www.pewresearch.org/internet/2013/01/15/health-online-2013-2/. Accessed 17 Mar 2020.
IQVIA Report. The impact of Biosimilar Competition in Europe. 2018.
Mehr S. An interesting comparison: the latest data on US and EU biosimilar uptake. Biosimilars Research and Review. April 23, 2020. https://biosimilarsrr.com/2020/04/23/an-interesting-comparison-the-latest-data-on-us-and-eu-biosimilar-uptake/. Accessed 18 May 2020.